September 9th, 2021 | 12:08 CEST
SMA Solar, Memiontec, CureVac: Doing good and earning money
When young founders develop business models, it is often a question of "purpose," i.e. the best possible (good) purpose of a company. For the new generation, money is no longer the only thing that counts. Instead, earning money and doing good are the watchwords. On the stock market, too, some companies make the world a little better. We look at three stocks and find out whether there is money to be made in them.
time to read: 3 minutes
|
Author:
Nico Popp
ISIN:
SMA SOLAR TECHNOL.AG | DE000A0DJ6J9 , Memiontec Holdings Limited | SGXE56008290 , CUREVAC N.V. O.N. | NL0015436031
Table of contents:
"[...] We have built one of the largest land packages of any non-producer in the belt at over 440 sq.km and have made more than 25 gold discoveries on the property to date with 5 of these discoveries totaling about 1.1 million ounces of gold resources. [...]" Jared Scharf, CEO, Desert Gold Ventures Inc.
Author
Nico Popp
At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.
Tag cloud
Shares cloud
SMA Solar: Thoughts after the profit warning
The share of SMA Solar recently had to give ground. The Company published a profit warning. The business with solar inverters is not going as well as planned. The expected sales are now still 10 to 12 % below the previously targeted goals. The lower sales have an even more significant impact on the expected profit: Instead of EUR 75 to 95 million, it is now expected to be EUR 50 to 65 million. If the lower figures are taken as a basis, this represents a drop of one-third. But how should investors react now?
The share price has fallen by around 15% since the profit warning. Cautious investors could wait until the price accurately reflects the lower expected earnings. But that is rarely how the stock market works. Either the market expects the lost profits to be postponed into the next year and turns earlier, or it even comes to an exaggeration. To assess this, one either dives deep into the fundamental situation at SMA Solar or orients oneself to chart technical marks. Fundamentally, the Company is supported because it has just achieved the turnaround - setbacks are typical in such a phase. In addition, the new growth course is to be supported by all three business segments, i.e. rooftop systems, commercial systems, and large-scale power plants - so there is no problem child. From a chart perspective, the share has found support above support levels between EUR 35 and 36. If this continues, the Company, which aims to be completely CO2-neutral by 2025, could take off again.
Memiontec: Clean water megatrend
Memiontec is a company that is also committed to doing good and at the same time operates in a fascinating economic region. The water treatment specialists from Singapore operate in the Asian region and have been on the market for more than twenty years. In Indonesia, in particular, the Company works with government agencies and is constantly moving projects forward. However, the Company recently won two new tenders with a total volume of SGD 12.7 million from Singapore.
As the Company is currently valued at only around EUR 60 million on the stock market, the major order caused the share price to jump. In the meantime, the share has consolidated at this level and is trending sideways. In view of the technological competence - Memiontec uses biological, chemical and physical processes for water treatment - and the general trend towards sustainability, the share can be considered an exciting growth stock. Especially in Asia, the issue of clean water is essential given rapidly growing mega-cities. Investors can make a note of Memiontec. Every new order can lead to a new valuation.
CureVac: Is a comeback on the way?
CureVac's failed first Corona vaccine project was the main reason for its revaluation. But anyone who writes the Company off because of this is making a mistake. The Tübingen-based Company still believes that it can help with possible mutations with vaccines. The mRNA technology also has many applications, such as a hope in the fight against cancer. The CureVac share has made a slight comeback in recent weeks. It will now be necessary for the stock to maintain its current level above EUR 57. The signs are good for a continuation of the recovery. However, the share is not a sure-fire winner.
Doing good and earning money - various companies combine both, and investors are spoiled for choice. While former shooting stars have yet to prove they can get back on track after setbacks, newcomers such as Memiontec's water purifiers are gradually winning over more investors. Where the journey can lead when good products meet high demand is shown by the share price performance of many former stock market shooting stars.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.
Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.
Risk notice
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.
The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.
